Member Info for Hazbeen

Right decision Andy !

Sell up what you have left.

This project will never be constructed. !

I mean look at the test plant , still cannot get small scale pilot plant that cost millions to construct working anywhere close to full capacity

That’s a warning sign already

Just have a ,ok in the shock market , how many junior miners become productive ers that make any money and shareholders have made money from. Become or remain a heavily debt ridden and over diluted penny share

So many clueless investors and traders here

Bigshow

Know as much as you … nowt

buy high , sell low trader

You are all deluded

I will be selling , but the debt will be highly expensive and the IRR is not great and always worse on production when it happens

Costs will end up the time this even starts a construction

The DFS will be very costly with 100m funding required .

Vanadium prices are not positive either

Any price will be driven by traders …still years away of any production after construction does ever get built

Like I said the pilot plant has been poor and decades to build and try to optimise

Lower EPS and zenith

No reason to buy right now

A presentation of results is always positive for me , company ready to take questions

As well as.

It is the forward outlook that I am interested in and looking to forward hear about

Hopefully we will get some info on this

The more I read about this company , the more I believe it’s technology will be so huge globally

Guys found this article many years back in 2019 about this fungus .

And OBI has the solution to fight it .

Health sector globally should be begging to get STERIWAVE in everywhere ASAP

https://www.bbc.co.uk/news/health-49170866

The C. Auris numbers are small in comparison what the numbers the US and rest of world numbers will be

For everyday patient submissions and ICU patients

The numbers have potentials to be huge in revenues

Highly effective against Candidozyma auris, a drug-resistant fungus that has seen cases surge across Europe.

It looks like this has been forgotten about or under the radar , and with the surge in the EU, it is bringing this news back to the forefront globally

Thx Reserved

A recent study at Royal Columbian Hospital (RCH) in Canada evaluated Steriwave® in the ICU and found it was effective at reducing nasal pathogens without resistance, showing a positive step toward better infection control in critically ill patients. While RCH is the first to test Steriwave® in the ICU setting, the broader results from previous trials at the hospital and elsewhere demonstrated significant improvements in surgical outcomes, including reduced hospital length of stay, lower readmission rates, and decreased antibiotic use

That may have been an oversight by the company or the transaction never took place or HCA have added about 4m in recent funding or only invested this time

Because HCA (hlinsught LLC) have 8.15% holdings now with 42,272,654 shares

Back in January

The Company has agreed to issue 38,033,412 new common shares of no par value in the capital of the Company ("New Common Shares"), raising US$4 million (circa £3,232,840) at an issue price of approximately US$0.10517 per New Common Share (the "Private Placement"). The price of the subscription was determined by reference to the price the Company raised C$19.2 million in November 2024. The New Common Shares to be issued pursuant to the Private Placement will represent approximately 8.6041 per cent of the share capital of the Company as enlarged by the Private Placement. The shares will be issued non pre-emptively under the Company's existing authorities and are expected to be admitted to trading on AIM on 29 January 2025.

So who was this background buyer ,

Will he come back for more after results ?, below expectations as they were

Agree

Cash up, but rest not exciting

EPS down slightly

Brilliant , great support at these levels now

Spring is only a few months away to receive FDA results

Guess many missed the 833k buy @9p

Explains bid up this morning

That’s outdated

Recent update states 13% market share

0.6% lower than last year